AI-Driven bioX Genetics Platform Slashes Genetic Variant Detection Time

Darzalex Faspro Achieves Outstanding Results in Multiple Myeloma with 95% 4-Year PFS

Targeted ADC ZL-1310 Shows Promising 67% ORR in Heavily Pretreated ES-SC Lung Cancer

IMforte Study: Tecentriq Plus Lurbinectedin Extends Survival in ES-SC Lung Cancer

Vividion and Bayer Advance First-in-Class WRN Inhibitor VVD-214 for Solid Tumors

AMPLITUDE: Niraparib Combo Improves rPFS in HRR-Altered mCS Prostate Cancer

ARANOTE Trial: Darolutamide Shows Significant Quality-of-Life Improvements in mCS Prostate Cancer

FDA Approves Darolutamide Plus ADT for mCS Prostate Cancer

Enhertu-pertuzumab Combo Shows 44% Risk Reduction in HER2+ Breast Cancer

ATOMIC Trial: Atezolizumab Combo Halves Recurrence in Stage III dMMR Colon Cancer

Imdelltra Extends Survival in Small Cell Lung Cancer, Cutting Death Risk by 40%

BioNTech and BMS Forge Partnership to Advance BNT327 for Solid Tumors

OASIS-4 Trial: Elinzanetant Reduces Hot Flashes in Breast Cancer Treatment

World-First Clinical Trial Confirms Exercise Boosts Survival in Colon Cancer

ctDNA-Guided Camizestrant Switch Redefines 1st-Line Breast Cancer Treatment

Pasritamig’s Favorable Safety and Efficacy in Advanced Prostate Cancer

Inavolisib Combination Doubles PFS in PIK3CA Mutated Advanced Breast Cancer

Libtayo Demonstrates 68% Risk Reduction in High-Risk CS Cell Carcinoma

START and OneOncology Partnership Expands Clinical Trials from Academia to Community

Improving Everolimus Safety in Oncology: Missed Opportunities in Risk Minimization

DNA-Based Immunotherapy IMNN-001 Shows Survival Gains in Advanced Ovarian Cancer

How the Integration of START and CURC Is Advancing Cancer Research and Clinical Trials

MB-105 CAR-T Therapy: Advancing Precision Treatment for CD5+ T-Cell Lymphoma

FDA Approves First Blood Test for Alzheimer’s, Marking a Historic Shift in Early Detection

EU Commission Approves Opdivo Regimen for High-Risk Resectable NSCLC

ONCOLife Warmly Welcomes Dr İlkiz Er Dağ as ONCOLife Project Director

FDA Approves Emrelis as the First Targeted ADC for High c-Met Expressing Lung Cancer

START Doses First Patient in Trial of mRNA-4106, a Pan-Tumor Therapy for Solid Tumors

The Latest Issue of ONCOLife Is Now Live – Follow the Cutting Edge of Oncology Innovation

10-Year Results Confirm Pertuzumab Combo Extends Survival in HER2+ Breast Cancer